| ID Source | ID |
|---|---|
| PubMed CID | 650604 |
| CHEMBL ID | 1299478 |
| CHEBI ID | 114723 |
| Synonym |
|---|
| 2-(5,6-dimethyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidin-2-ylsulfanyl)-n-(4-methyl-thiazol-2-yl)-acetamide |
| MLS000070919 , |
| smr000006140 |
| CHEBI:114723 |
| 2-[(5,6-dimethyl-4-oxo-3h-thieno[2,3-d]pyrimidin-2-yl)sulfanyl]-n-(4-methyl-1,3-thiazol-2-yl)acetamide |
| CHEMBL1299478 |
| HMS2386M12 |
| 2-[(5,6-dimethyl-4-oxidanylidene-3h-thieno[2,3-d]pyrimidin-2-yl)sulfanyl]-n-(4-methyl-1,3-thiazol-2-yl)ethanamide |
| cid_650604 |
| bdbm88816 |
| 2-[(5,6-dimethyl-4-oxo-3h-thieno[2,3-d]pyrimidin-2-yl)thio]-n-(4-methyl-2-thiazolyl)acetamide |
| 2-[(4-keto-5,6-dimethyl-3h-thieno[2,3-d]pyrimidin-2-yl)thio]-n-(4-methylthiazol-2-yl)acetamide |
| acetamide,2-[(1,4-dihydro-5,6-dimethyl-4-oxothieno[2,3-d]pyrimidin-2-yl)thio]-n-(4-methyl-thiazol-2-yl)- |
| Q27196128 |
| Class | Description |
|---|---|
| organosulfur heterocyclic compound | |
| organonitrogen heterocyclic compound | Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. |
| organic heterobicyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 2.5119 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 2.5119 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 19.9526 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 31.6228 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 17.7828 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 100.0000 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 1.4444 | 0.0355 | 20.9770 | 89.1251 | AID504332; AID588344 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 39.8107 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 8.9125 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 79.4328 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 2.3778 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 7.5686 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 70.7946 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Potency | 11.2202 | 6.3096 | 15.3445 | 35.4813 | AID743286 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PSMD14 protein | Homo sapiens (human) | IC50 (µMol) | 24.3000 | 1.3000 | 21.8715 | 50.9000 | AID602368 |
| TPA: prothrombin | Bos taurus (cattle) | IC50 (µMol) | 43.6000 | 4.8100 | 36.7432 | 77.4000 | AID602369 |
| 72 kDa type IV collagenase isoform 1 preproprotein | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 5.7900 | 38.9633 | 78.4000 | AID602361 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| ATP binding | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| 1-phosphatidylinositol-4-phosphate 5-kinase activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| 1-phosphatidylinositol-5-phosphate 4-kinase activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| protein homodimerization activity | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| photoreceptor outer segment | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| photoreceptor inner segment | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| nucleoplasm | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| lysosome | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| autophagosome | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| cytosol | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| plasma membrane | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| plasma membrane | Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||